FIELD: medicine.
SUBSTANCE: according to a known method of treating the liver disease accompanying type 2 diabetes mellitus involving the baseline therapy of diabetes mellitus and prescribed hepatoprotectors, the above hepatoprotector is presented by Mexicor in a daily therapeutically effective dose of not less than 16 weeks. The therapeutically effective dose of Mexicor makes 100 mg 4 times a day.
EFFECT: higher clinical effectiveness ensured by eliminating the liver disease more prominently, reducing the length of treatment, normalising the liver function test results over a short period of time, and avoiding any side effects.
2 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATOPROTECTOR FOR TREATING NON-ALCOHOLIC LIVER DISEASE IN TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2537227C1 |
| METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
| METHOD FOR DIAGNOSING HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH TYPE 2 DIABETES MELLITUS | 2019 |
|
RU2732526C1 |
| DIAGNOSTIC TECHNIQUE FOR FATTY HEPATOSIS | 2014 |
|
RU2578080C2 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
| METHOD OF EARLY DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2022 |
|
RU2798723C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR ALCOHOLIC LIVER DISEASE | 2013 |
|
RU2530646C1 |
| METHOD OF DIAGNOSING DEGREE OF EXPRESSION OF FATTY HEPATOSIS IN PEOPLE WITH DIABETES MELLITUS | 2012 |
|
RU2495626C1 |
